Koncern nyheter

| 1 - 10 | 11 - 20 | 21 - 30 | 31 - 40 | 41 - 50 |

07-maj-2013
Bayer documents economic, social and ecological performance
Bayer CEO Dekkers: “Innovation and sustainability are the driving force behind our business success” / Integrated reporting from 2014

26-apr-2013
“Bayer is a world-class innovation company”
2012 operationally a very successful year / Highest sales in the company’s 150-year history / Proposal to raise dividend for 2012 to EUR 1.90 per share / Employees to benefit from the company’s success with bonuses totaling over EUR 700 million / Life Sciences off to a good start in anniversary year

25-apr-2013
Bayer: Life Sciences off to a good start in anniversary year
New pharmaceutical products spur growth at HealthCare, continuing strong development at CropScience, cost pressure at MaterialScience / Group sales up 2.1 percent to EUR 10,266 million / EBIT improves by 8.6 percent to EUR 1,771 million / EBITDA before special items increased by 0.4 percent to EUR 2,453 million / Net income rises 11.5 percent to EUR 1,160 million / Gratifying development in Emerging Markets / Group outlook for 2013 confirmed

28-mar-2013
Bayer CropScience and Syngenta propose a comprehensive action plan to help unlock EU stalemate on bee health

25-mar-2013
Bayer’s Stivarga® (regorafenib) Tablets Approved in Japan for the Treatment of Advanced or Recurrent Colorectal Cancer (for specialized target groups only)

15-mar-2013
Bayer CropScience welcomes the proportionate response of Member States on EU Commission proposal on neonicotinoids
The company will continue to engage further in dialogue to support the safe use of neonicotinoid products

28-feb-2013
Bayer: continuing growth momentum
Group targets achieved in 2012 – sales and earnings before special items increase in all subgroups / Sales increase by 8.8 percent to EUR 39,760 million / EBIT EUR 3,960 million (minus 4.6 percent) – Net income EUR 2,446 million (minus 1.0 percent) / Further accounting measures for legal claims / EBITDA before special items rises by 8.8 percent to EUR 8,284 million / Core earnings per share improve by 10.8 percent to EUR 5.35 / Encouraging growth in the emerging markets / Steady progress with innovation pipeline strengthens life-science businesses / Forecast for anniversary year 2013: continuing record development

26-feb-2013
Bayer proposes dividend increase to EUR 1.90 per share for 2012
Payout up 15 percent to EUR 1,571 million

22-feb-2013
Bayer Thrombosis Research Award 2013 for Dr. Krystin Krauel
Research scientist at Ernst-Moritz-Arndt University Greifswald honored for her work in the field of antibacterial host defenses

01-feb-2013
Positive results of Phase-III trials suggest that ATX-101 is effective as a non-surgical treatment for the reduction of unwanted submental fat (for specialized target groups only)